Millennium Management’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-136,978
| Closed | -$2.56M | – | 6367 |
|
|
2025
Q4 | $2.56M | Buy |
136,978
+112,486
| +459% | +$1.87M | ﹤0.01% | 3725 |
|
|
2025
Q3 | $358K | Sell |
24,492
-19,315
| -44% | -$244K | ﹤0.01% | 5262 |
|
|
2025
Q2 | $483K | Sell |
43,807
-247,727
| -85% | -$2.41M | ﹤0.01% | 4939 |
|
|
2025
Q1 | $2.6M | Buy |
291,534
+98,695
| +51% | +$918K | ﹤0.01% | 3530 |
|
|
2024
Q4 | $1.81M | Buy |
192,839
+80,140
| +71% | +$729K | ﹤0.01% | 3731 |
|
|
2024
Q3 | $908K | Buy |
112,699
+50,430
| +81% | +$437K | ﹤0.01% | 4357 |
|
|
2024
Q2 | $528K | Buy |
62,269
+2,249
| +4% | +$20.3K | ﹤0.01% | 4548 |
|
|
2024
Q1 | $538K | Sell |
60,020
-60,145
| -50% | -$557K | ﹤0.01% | 4762 |
|
|
2023
Q4 | $1.35M | Sell |
120,165
-107,498
| -47% | -$1.08M | ﹤0.01% | 3926 |
|
|
2023
Q3 | $1.96M | Buy |
227,663
+209,894
| +1,181% | +$2.03M | ﹤0.01% | 3565 |
|
|
2023
Q2 | $184K | Sell |
17,769
-121,937
| -87% | -$1.35M | ﹤0.01% | 5152 |
|
|
2023
Q1 | $1.52M | Sell |
139,706
-535,784
| -79% | -$5.67M | ﹤0.01% | 3698 |
|
|
2022
Q4 | $7.58M | Buy |
675,490
+24,932
| +4% | +$262K | ﹤0.01% | 2424 |
|
|
2022
Q3 | $6.6M | Buy |
+650,558
| New | +$6.1M | ﹤0.01% | 2624 |
|
|
2022
Q2 | – | Sell |
-17,805
| Closed | -$170K | – | 7487 |
|
|
2022
Q1 | $170K | Sell |
17,805
-5,688
| -24% | -$55.7K | ﹤0.01% | 5903 |
|
|
2021
Q4 | $260K | Sell |
23,493
-922,041
| -98% | -$8.04M | ﹤0.01% | 5674 |
|
|
2021
Q3 | $7M | Buy |
945,534
+794,983
| +528% | +$8.89M | ﹤0.01% | 2492 |
|
|
2021
Q2 | $2.19M | Buy |
150,551
+31,682
| +27% | +$595K | ﹤0.01% | 3854 |
|
|
2021
Q1 | $2.43M | Buy |
118,869
+94,617
| +390% | +$1.8M | ﹤0.01% | 3354 |
|
|
2020
Q4 | $431K | Buy |
24,252
+7,584
| +46% | +$136K | ﹤0.01% | 4313 |
|
|
2020
Q3 | $246 | Buy |
+16,668
| New | +$312K | ﹤0.01% | 3966 |
|
|
2020
Q1 | – | Sell |
-100,551
| Closed | -$2.6M | – | 4459 |
|
|
2019
Q4 | $2.6M | Buy |
+100,551
| New | +$1.95M | ﹤0.01% | 2441 |
|
|
2019
Q2 | – | Sell |
-16,623
| Closed | -$377K | – | 4435 |
|
|
2019
Q1 | $377K | Buy |
+16,623
| New | +$421K | ﹤0.01% | 3424 |
|
|
2018
Q4 | – | Sell |
-131,596
| Closed | -$4.3M | – | 4162 |
|
|
2018
Q3 | $4.3M | Buy |
131,596
+88,430
| +205% | +$2.41M | 0.01% | 1922 |
|
|
2018
Q2 | $979K | Sell |
43,166
-23,958
| -36% | -$569K | ﹤0.01% | 2848 |
|
|
2018
Q1 | $1.63M | Buy |
67,124
+52,086
| +346% | +$1.43M | ﹤0.01% | 2433 |
|
|
2017
Q4 | $419K | Buy |
+15,038
| New | +$445K | ﹤0.01% | 3179 |
|
|
2017
Q1 | – | Sell |
-19,420
| Closed | -$619K | – | 3826 |
|
|
2016
Q4 | $619K | Buy |
+19,420
| New | +$602K | ﹤0.01% | 2553 |
|
|
2016
Q1 | – | Sell |
-62,978
| Closed | -$1.03M | – | 3644 |
|
|
2015
Q4 | $1.03M | Sell |
62,978
-60,259
| -49% | -$956K | ﹤0.01% | 2287 |
|
|
2015
Q3 | $1.35M | Buy |
123,237
+77,906
| +172% | +$992K | ﹤0.01% | 2125 |
|
|
2015
Q2 | $590K | Sell |
45,331
-5,165
| -10% | -$80.1K | ﹤0.01% | 2551 |
|
|
2015
Q1 | $876K | Sell |
50,496
-97,853
| -66% | -$1.79M | ﹤0.01% | 2396 |
|
|
2014
Q4 | $2.21M | Buy |
148,349
+138,060
| +1,342% | +$2.41M | ﹤0.01% | 1907 |
|
|
2014
Q3 | $237K | Buy |
+10,289
| New | +$299K | ﹤0.01% | 3281 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
VCM
Millennium Management's TBPH Position: Q1 2026 in Review
Millennium Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 136,978 shares — an estimated $2.56M sold.
Millennium Management first reported a position in TBPH in Q3 2014 and held it in 34 quarters. The position peaked at $7.58M in Q4 2022. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.
- Millennium Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
- Millennium Management sold 136,978 Theravance Biopharma shares in Q1 2026, an estimated $2.56M.
- Millennium Management first reported a position in Theravance Biopharma in Q3 2014 and held it in 34 quarters.
- Millennium Management's Theravance Biopharma position peaked at $7.58M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.